The relative efficacy and harms of balloon kyphoplasty (BK) for treating vertebral compression fractures (VCF) are uncertain. We searched multiple electronic databases to March 2016 for randomised and quasi-randomised controlled trials comparing BK with control treatment (non-surgical management [NSM], percutaneous vertebroplasty [PV], KIVA®, vertebral body stenting, or other) in adults with VCF. Outcomes included back pain, back disability, quality of life (QoL), new VCF and adverse events (AE). One reviewer extracted data, a second checked accuracy, and two rated risk of bias (ROB). Mean differences and 95% confidence intervals were calculated using inverse-variance models. Risk ratios of new VCF and AE were calculated using Mantel-Haenszel models. Ten unique trials enrolled 1,837 participants (age range: 61-76 years, 74% female), all rated as having high or uncertain ROB. Versus NSM, BK was associated with greater reductions in pain, back-related disability, and better QoL (k=1 trial) that appeared to lessen over time, but were less than minimally clinically important differences. Risk of new VCF at 3 and 12 months was not significantly different (k=2 trials). Risk of any AE was increased at 1 month (RR=1.73 [1.36, 2.21]). There were no significant differences between BK and PV in back pain, back disability, QoL, risk of new VCF or any AE (k=1 to 3 trials). Limitations included lack of a BK versus sham comparison, availability of only one RCT of BK versus NSM, and lack of study blinding. Individuals with painful VCF experienced symptomatic improvement compared with baseline with all interventions. The clinical importance of the greater improvements with BK versus NSM is unclear, may be due to placebo effect, and may not counterbalance short-term AE risks. Outcomes appeared similar between BK and other surgical interventions. Well-conducted randomized trials comparing BK with sham would help resolve remaining uncertainty about the relative benefits and
Introduction
In the United States, vertebral compression fractures (VCF) account for nearly half of the approximately 1.5 million osteoporotic fractures every year (1) . VCF can cause acute and chronic pain, physical impairment and disability, adversely impact quality of life, and are associated with an increased risk of future vertebral and non-vertebral fractures (2) .
Medical treatments of VCF may reduce pain (3), but many patients still experience severe and sometimes long-lasting symptoms. Alternatively, several "vertebral augmentation" procedures have been developed to treat patients with symptomatic VCF. The simplest of these is percutaneous vertebroplasty (PV), in which bone cement is percutaneously injected inside the fractured vertebral body. Balloon kyphoplasty (BK) involves inflation of a balloon inside the fractured vertebral body and balloon removal before injection of bone cement. With vertebral body stenting (VBS), balloon inflation and removal is followed by insertion of an expandable scaffold before injection of bone cement (4) . With KIVA®, a nesting, vertically oriented, cylindrical column is inserted over a coil into the fractured vertebral body before injection of bone cement (5) .
Vertebral augmentation procedures may reduce pain and back-related disability by restoring vertebral height and stabilizing fractured vertebrae, but risks may include cement leakage associated nerve-root injury, rarely symptomatic pulmonary embolism, and a possible increase in frequency of subsequent vertebral fractures attributable to procedurerelated alterations in spine biomechanics (6) . Of approximately 300,000 inpatient vertebral augmentation procedures performed in the U.S. between 2005 and 2010, 73% were BK and 27% were PV (7) .
Given that BK is the most commonly performed vertebral augmentation procedure, we undertook this systematic review to compare its efficacy, relative efficacy and harms versus other treatments for VCF in middle-aged and older adults, including versus nonsurgical management (NSM), sham control, PV and other vertebral augmentation techniques.
Methods

Data sources
We followed the PRISMA guidelines (8 November 2014 using the title/abstract search terms: [("kyphoplasty") AND ("randomized" OR "controlled") AND NOT "malignancy" AND NOT "review"] with no language restriction. We updated this search in March 2016.
Study selection and inclusion criteria
We included randomised controlled trials (RCTs) and quasi-randomised trials that enrolled adults aged >40 years with non-traumatic vertebral fractures and compared BK versus any treatment for at least one validated measure of pain, disability, physical function, health-related quality of life, participant-reported treatment success, balance, falls, posture, bone mineral density (BMD), incident clinical or radiographic vertebral fractures, or adverse events (AE). Two reviewers independently examined titles, abstracts, and full articles for eligibility and resolved discrepancies by discussion and consensus.
Data extraction and risk of bias assessment
Two reviewers independently extracted data on study design, participant characteristics, intervention characteristics, outcomes and adverse events, and an additional reviewer checked accuracy.
Studies were evaluated for risk of bias using the Cochrane Collaboration Risk of Bias Tool (The Cochrane Collaboration, v5.1.0), with potential sources of bias including random sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessments, and completeness of reported outcomes data (9) . For each domain, risk of bias was rated as high, low or unclear by two independent investigators and agreed to in a consensus meeting. When there were multiple reports for a single study, information from all reports was used to rate risk of bias for each domain for that study. Risk of bias was summarized for individual studies as low (low risk of bias for all domains), unclear (unclear risk of bias for >1 domain) or high (high risk of bias for >1 domain).
Data analysis
For continuous outcomes, mean differences (MD) and 95% confidence intervals (CI) were calculated using inverse-variance models. For dichotomous outcomes, risk ratios (RR) and 95%CI were calculated using Mantel-Haenszel models. Statistical heterogeneity was determined by the I 2 statistic, applying random-effects models when I 2 > 50% (9). When there were multiple reports of a single study, the most recent publication was used as the primary data source and the other reports were used to provide supplemental information.
Results
Literature search
Together, the initial and updated database searches yielded 2,460 unique references.
We excluded 2,406 during title and abstract review and 40 during full-text review, leaving 14
reports of 10 unique studies that met eligibility criteria and were included for analysis (4, 5, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) [ Figure 1 ]. Characteristics of included studies are described in Table 1 .
Risk of bias
Among the 10 unique eligible studies, the most common source of bias was lack of blinding, followed by inadequate or uncertain concealment of treatment allocation, and incomplete reporting of outcomes [ Table 2 ], though it was not possible to mask assessors of radiographic outcomes to the vertebral cement in participants assigned to BK or other vertebral augmentation procedures. No trials were rated as having low risk of bias, two were rated as having unclear risk of bias (5, 14, 22) , and eight were rated as having high risk of bias (4, 10-13, 16-21).
Kyphoplasty versus Placebo or Sham
We identified no eligible trials that compared BK versus a sham BK procedure.
Kyphoplasty versus Non-surgical management
Study characteristics
Five reports met eligibility criteria, four of which were duplicate publications from the FREE trial (10, 11, 17, 20) , so that there were two unique trials. Both were rated as having high risk of bias. The FREE trial (n=300) used computer generated permuted block randomization, after which participants and study staff were unblinded. Follow-up was 24
months. The Yi trial (n=200) stated that participants were randomized, but also that treatment assignment was blindly chosen by a single surgeon (21) . Outcome assessors but not participants were blinded to treatment assignment and follow-up was 48 months [ Table 2 ].
Patient characteristics
In the FREE trial, mean age was 72.2 years, and 77% of participants were female (10, 11, 17, 20) . Qualifying vertebral fractures were <3 months old (mean 6 weeks) and most commonly located at the thoracolumbar junction. Vertebral fractures were attributed to osteoporosis (approximately 40% of participants had a spine T-score of <-2.5) (10, 20 (10, 17, 20) [Supplementary Table 7] .
Kyphoplasty versus Vertebroplasty
Study characteristics
Six reports (12, 14, 15, 18, 19, 21) met eligibility criteria, including five unique RCTs, (n=857) and one quasi-randomized study (n=112) (13) . All six trials were rated as having high risk of bias. Two trials were single-blinded (19, 21) , two trials were unblinded (12, 18), and two trials had no blinding specified (13) (14) (15) . Treatment allocation was performed by computerised block randomisation in two studies (12, 14, 15) , assigned by the operating surgeon in two studies (13, 21), and was not specified in two studies (18, 19) . Follow-up duration ranged from six to 60 months (14, 15) [ Table 2 ].
Patient characteristics
Mean participant age was 71.6 years and about 75% were female. Qualifying VCF were acute (<6 weeks old) or subacute (6-12 weeks old) (12) (13) (14) (15) , with some studies requiring or reporting supportive findings on MRI (12, 13, 19, 21) . Fractures were most commonly located near the thoracolumbar junction. Three studies limited participation to individuals who had failed several weeks of conservative therapy (13, 18, 19) . Three studies were limited to or were mostly comprised of participants with osteopenia or osteoporosis (12, 18, 19 (14) , but there were no statistically significant differences at other time points (12, 15, 19) [ Figure 2 ]. In the quasi-randomised study, there were no statistically significant differences (p<0.05) in VAS scores between treatment groups at any follow-up time point, but there was a statistically significant difference between groups in change from baseline to two year follow-up (0.60 [0.22, 0.98]; n=86) that was small and not likely to have been clinically meaningful (13).
Back-related disability
In two RCTs (12, 19) and one quasi-randomized study (13) , there was no statistically significant difference between treatments in improvement in ODI from baseline to any time points ranging between three months and two years [Supplementary Table 8 ].
Quality of life
There was no statistically significant difference between treatments in improvement in SF-36 PCS or EQ-5D at any time point (12) [Supplementary 
Adverse events
Only one study reported data on adverse events, and found no increased risk of serious AE at 30 days (26.2% vs. 27.4%, p=0.82) (12, 28) . This trial reported the most common individual types of AEs within 30 days of surgery as procedural pain 6% for BK vs.
5% for VP, back pain 7% for BK vs. 15% for VP, and new symptomatic fracture 5% for BK vs. 9% for VP. Within 2 years of surgery, there did not appear to be a significant difference between treatment groups in risk of falls, pneumonia, bronchitis, or urinary tract infection.
Kyphoplasty versus Vertebral body stenting
One eligible trial (n=63, 100 treated levels) randomized participants to BK versus VBS, and reported only that there were no neurologic sequelae in the immediate postoperative period (4) [ Table 2 ]. This trial was rated as having high risk of bias for lack of blinding of outcome assessment.
Kyphoplasty versus KIVA
Study characteristics
Two eligible trials randomized participants to BK versus KIVA (5, 16) . One trial was blinded to participants, investigators and outcome assessors and (5) was rated as having unclear risk of bias due to unclear allocation of treatment assignment, while the other was blinded only to participants, and then only until after the procedure was completed (16) , and was therefore rated as having high risk of bias. Follow-up was 14 and 12 months, respectively [ Table 2 ].
Patient characteristics
Mean participant age was 73.7 years and 72.8% were female. Qualifying vertebral fractures were acute or subacute, and, in the one study that reported location, most commonly around the thoracolumbar junction (16) . One trial limited participation to individuals who had failed conservative treatment, and reported a mean spine T-score in the osteopenic range. At baseline, participants reported severe back pain (mean VAS 8.6) and considerable backrelated disability (mean ODI 63%) (16) .
Outcomes Back pain, Back-related disability, and Quality of life
There was no difference between treatment groups in the proportion of participants with >5.5 points improvement in back pain (VAS) (43% for BK vs. 54% for KIVA; RR=0.80
[0.58, 1.10] (5)), with >1.5 points improvement in back pain (VAS) (97.6% vs. 95.3% (16)), or with undefined "improved" SF-36 PCS (59% for BK vs. 51% for KIVA (5)). There also was no between-group difference in achievement of a composite endpoint requiring a 1.5 point improvement in VAS, and absence of either a >10 point worsening in ODI or a device-related AE (16) , and no between-group difference in mean improvement from baseline in back pain (VAS) (5, 16), back-related disability (ODI) (5, 16), or quality of life (SF-36 PCS) (5, 16).
Incident vertebral fractures
There was no difference between BK and KIVA participants in risk of incident radiographic vertebral fractures (12.8% vs. 12.2%, p=0.91) or incident adjacent radiographic vertebral fractures (17.1% vs. 15.7%, p=0.64) (5).
Adverse events
There was no difference in serious adverse events between BK and KIVA participants through 12 months (34.6% vs. 28.6%; RR=1.21; 0.84, 1.75; events= 80; n= 253] (16).
Individual types of AEs were reported only if judged by trial investigators to be procedurerelated, including three participants randomized to KIVA with herpes zoster, post-procedural pain, and pruritus, respectively, and four assigned to BK with an airway complication, back pain, ischemic stroke, and rash, respectively (16).
Discussion
On average, individuals with painful VCF experienced statistically significant symptomatic improvement compared with baseline with all studied treatment interventions, including NSM. Though we found that BK was associated with improved pain, back-related disability and quality of life outcomes compared with NSM, these results were derived almost entirely from a single trial. Further, magnitude of improvement from baseline in these outcome measures after BK relative to NSM appeared to diminish over time, mean between group differences were smaller than previously reported minimally clinically important differences in a population of individuals being treated for chronic low back pain (29) AEs. This hampered our ability to weigh the relative harms of BK against any potential benefits. Fourth, most trials were rated as having high risk of bias, most commonly due to lack of blinding of participants and/or outcome assessors, and less often due to a lack of allocation concealment, both which could have led to overestimation of the true effect of interventions..
In conclusion, we found that in middle-aged and older adults with VCF, based on only a single RCT, BK was associated with greater improvement in pain, disability and quality of life and an increase in risk of early AE compared with NSM. However, the magnitude of treatment differences may have been too small to be clinically meaningful, diminished over time, and likely was attributable at least in part to a placebo effect. Based on a small number of heterogeneous (and high risk of bias) studies, there was no difference in these outcomes between BK and either the PV or KIVA vertebral augmentation techniques. Risks of subsequent fracture were not statistically significantly different between BK and other treatments, but results could not rule out important differences. These remaining areas of uncertainty should be addressed by future trials that randomize participants with acute and subacute painful VCF to BK versus sham BK, PV or KIVA®, mask study participants, investigators and outcome assessors, follow participants for at least one year, include adequately powered responder analyses for efficacy outcomes (e.g. proportion achieving a clinically important improvement in back pain), systematically collect results for clinical and radiographic vertebral fracture and AE, and include a priori subgroup analyses for patient groups with characteristics suspected to modify the effects of treatment. Mean changes in back pain scores from baseline at 1, 3, 6, 12 and >12 months in kyphoplasty versus percutaneous vertebroplasty study groups. 
